Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-05-22
DOI
10.1038/s41598-019-44206-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses
- (2018) Natalia Aptsiauri et al. CURRENT OPINION IN IMMUNOLOGY
- Immune checkpoint blockade therapy
- (2018) Thomas Wieder et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung
- (2018) Ayako Hirai et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
- (2018) M Oliva et al. ANNALS OF ONCOLOGY
- PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
- (2017) Michal Šmahel INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma
- (2017) Edward Roper et al. PATHOLOGY
- Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis
- (2017) Ji Li et al. PLoS One
- PD‑L1 expression is associated with p16INK4A expression in non‑oropharyngeal head and neck squamous cell carcinoma
- (2017) San‑Chi Chen et al. Oncology Letters
- HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape
- (2017) Francisco Perea et al. Oncotarget
- Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
- (2017) Axel Lechner et al. Oncotarget
- Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer
- (2017) Stefanie Aust et al. Scientific Reports
- Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome
- (2016) Shuhei Ito et al. ANNALS OF SURGICAL ONCOLOGY
- Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy
- (2016) Yayan T. Sundara et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Rejection versus escape: the tumor MHC dilemma
- (2016) Federico Garrido et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming
- (2016) Michael D. Buck et al. CELL
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
- (2016) Laura Q.M. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype
- (2016) Marie Kostine et al. MODERN PATHOLOGY
- Emerging concepts of T cell metabolism as a target of immunotherapy
- (2016) Chih-Hao Chang et al. NATURE IMMUNOLOGY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- The epigenetic landscape of T cell exhaustion
- (2016) D. R. Sen et al. SCIENCE
- PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
- (2016) Hye Ryun Kim et al. Scientific Reports
- Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers
- (2015) Moon-Young Kim et al. LUNG CANCER
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Correlation between human papillomavirus and p16 overexpression in oropharyngeal tumours: a systematic review
- (2014) C Grønhøj Larsen et al. BRITISH JOURNAL OF CANCER
- Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
- (2014) G. L. Beatty et al. CLINICAL CANCER RESEARCH
- Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy
- (2014) Yuichiroh Umemoto et al. JOURNAL OF GASTROENTEROLOGY
- MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells
- (2013) P. Leone et al. JNCI-Journal of the National Cancer Institute
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Clinical implication of HLA class I expression in breast cancer
- (2011) Koichi Kaneko et al. BMC CANCER
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More